Fig. 2
From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease
Observed and predicted efficacy against clinical disease for 3-monthly periods. Field and predicted estimates of clinical efficacy at each 3-month follow-up for a the 6–12 weeks without booster; b 5–17 months cohort without booster, by the 9 trial site used in the fitting (excludes Kilifi and Manhica). Reported efficacy (mean and 95 % CI) in the trial site is indicated by black circles. Prediction estimates (mean and 95 % prediction intervals) are shown in colour for different fitted models, orange assuming exponential decay and blue fitting for decay shape